Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Synthetic polymer

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424400000 - PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM

424484000 - Matrices

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424487000 Acrylic acid and derivatives 76
Entries
DocumentTitleDate
20100062065PHARMACEUTICAL COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM - Provided is an oral pharmaceutical composition with improved bioavailability and pharmacokinetic properties of a drug, by increasing a bioabsorption rate and an in vivo retention time of an active ingredient via intestine-targeted formulation of a particular naphthoquinone-based compound, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as an active ingredient.03-11-2010
20090317470Oramucosal Pharmaceutical Dosage Form - This invention relates to an oramucosal pharmaceutical dosage form in the form of a wafer. The wafer comprises a porous, hydroscopic, muco-adhesive polymeric matrix with at least one desired pharmaceutically active compound added thereto. The polymer is selected from a number of polymers having different dissolution rates and, in use when taken orally, the matrix adheres to an oramucosal surface to dissolve over a predetermined period of time to release the pharmaceutically active compound. The invention also extends to a method of manufacturing an oramucosal pharmaceutical dosage form in the form of a wafer which involves freeze drying or lyophilisation.12-24-2009
20090123546Polymer-based, sustained release drug delivery system - Disclosed is a sustained release system that includes a polymer and a pharmaceutically active agent dispersed in the polymer. The agent is in granular or particulate form, and has a rate of release from the system that is limited primarily by the rate at which the agent dissolves from the granules into the polymer matrix. Advantageously, the polymer is permeable to the agent and is non-release-rate-limiting with respect to the rate of release of the agent from the polymer.05-14-2009
20090196928Biocompatible hydrogel compositions - Compositions, instruments, systems, and methods are providing for creating families of materials having diverse therapeutic indications and possessing enhanced biocompatibility. One genus platform for the families includes a biocompatible synthetic electrophilic component mixed with a nucleophilic component. The electrophilic component can include a functionalized electrophilic poly (anhydride ester) material. The nucleophilic material can include a natural, autologous protein. The components, when mixed in a liquid state, react by cross-linking, forming a solid matrix composition, or hydrogel.08-06-2009
20100112064TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING ION PAIR MICRORESERVOIRS - The invention relates to a transdermal therapeutic system which comprises a back layer that is impermeable to the active substance, and a peelable protective layer that is impermeable to the active substance and at least one matrix layer consisting of polysiloxanes and/or polysiloxane derivatives and containing micro-reservoirs. Said micro-reservoirs contain at least one ion pair from a pharmacologically active substance and an additive and either the active substance is nucleophilic and the additive is electrophilic or the active substance is electrophilic and the additive is nucleophilic.05-06-2010
20080260834VITAMIN D3 ANALOG LOADED POLYMER FORMULATIONS FOR CANCER AND NEURODEGENERATIVE DISORDERS - Localized delivery of 1,25 D10-23-2008
20080260833Drug delivery vehicle containing vesicles in a hydrogel base - A drug delivery vehicle having active agent loaded vesicles in a hydrogel matrix; desirably either or both of the vesicles and matrix are made of at least one stimulus responsive polymer so that active agent is released in response to contact with a stimulus.10-23-2008
20080260832SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR PREVENTING RETINAL DYSFUNCTION - Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.10-23-2008
20100055186PHOTOCROSSLINKABLE OLIGO(POLY (ETHYLENE GLYCOL) FUMARATE) HYDROGELS FOR CELL AND DRUG DELIVERY - The invention provides photocrosslinkable, injectable, biodegradable oligo(poly(ethylene glycol) fumarate) (OPF) hydrogels made from the photopolymerization of an OPF macromer with UV light and a photoinitiator. Hydrogels with varying mechanical properties and water content can be made with changes in macromer and crosslinking agent concentration in a precursor solution. The biodegradable OPF hydrogels can be injected as a fluid into a bodily defect of any shape, may incorporate various therapeutic agents, e.g., cells and/or growth factors, and may be implanted via minimally invasive arthroscopic techniques.03-04-2010
20110195124PHASE-TRANSITION POLYMERIC MICRONEEDLES - This invention discloses a novel microneedle system, phase-transition microneedle patch, which overcomes all the limitations that existing microneedles encountered. The microneedle patch is formed of an integrated polymeric piece consisting of a microneedle array and a plate (called holding plate) on which the needles stand. The microneedles of the patch are hard and strong enough to penetrate epidermis at dry state but turn to be hydrogel state soft and permeable to hydrophilic agents when absorbing body fluid. The hydrogel state of the patch is a hydrophilic network held by physical or chemical cross-linking junctions. The pores of the network are opened up by body fluid for drugs and macromolecules to diffuse through. The polymeric materials used to form the microneedle patch have been used in the pharmaceutical field for years and have proven compatibility with the skin and with proteins. The drugs may be stored in the matrix of the microneedle array as well as the holding plate so that the requirement for high dose applications may be full filled. In addition, molding (casting) of this type of microneedle patch is simple, easy to achieve and needs no microfabrication systems and organic solvents. By a programmed molding (casting), the patch may be assembled in a layered structure with desired drug concentration in each layer, respectively. Due to this design, a programmed pulse or a zero order release of drugs may easily be achieved. In addition, delicate proteins loaded in the patch are kept in a dry and hydrophilic glassy state before being released, the most favored state for protein storage. Finally, during the swelling-based drug release, the microneedle patch increases their thickness gradually between the skin and the back cover (which holds the needles) lo create a sustained pressure to ensure good contact of the microneedles inside epidermis.08-11-2011
20100074956FORMATION OF HYDROGEL IN THE PRESENCE OF PEROXIDASE AND LOW CONCENTRATION OF HYDROGEN PEROXIDE - In a process of forming a hydrogel from a mixture comprising hydrogen peroxide (H03-25-2010
20100112063METHOD FOR PREPARING A HYDROGEL ADHESIVE HAVING EXTENDED GELATION TIME AND DECREASED DEGRADATION TIME - A method for extending the gelation time of an oxidized polysaccharide to react with a water-dispersible, multi-arm amine to form a hydrogel is disclosed. The extension of the gelation time is accomplished by using a chemical additive. The method also extends the time for the hydrogel to become tack-free, and may also be used to decrease the degradation time of the hydrogel. The chemical additive reacts with the functional groups of the oxidized polysaccharide or the water-dispersible, multi-arm amine, thereby reducing the number of groups available for crosslinking. The use of the resulting hydrogel for medical and veterinary applications is described.05-06-2010
20080279943METHOD OF MAKING HYDROGEL IMPLANTS - Implantable biomaterials, particularly hydrogel substrates with porous surfaces, and methods for enhancing the compatibility of biomaterials with living tissue, and for causing physical attachment between biomaterials and living tissues are provided. Also provided are implants suitable for load-bearing surfaces in hard tissue repair, replacement, or augmentation, and to methods of their use. One embodiment of the invention relates to an implantable spinal disc prosthesis.11-13-2008
20090142400ANALGESIC COATED MEDICAL PRODUCT - Described are medical products including an analgesic such as lidocaine, bupivicaine, or a mixture thereof. Such medical products can find use in pain relief, particularly after surgery, and can be applied to tissue or can be implanted within a patient. Also described are medical products including an extracellular matrix material, one or more analgesic agents, and a carrier effective to extend the release of the agent(s). Related methods of manufacture and use are also described.06-04-2009
20100098763PHARMACEUTICAL FORMULATION 514 - The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.04-22-2010
20100112065Therapeutic ultrasound gel - The therapeutic ultrasound gel is a composition that lubricates the abdomen for ultrasound scanning, that enhances the transmission of sound waves during ultrasound diagnostic imaging, and that has beneficial therapeutic effects in preventing the formation of stretch marks. The composition contains effective amounts of 05-06-2010
20090155366OSTEOINDUCTIVE MATERIALS - The present invention concerns improved osteoinductive materials comprising matrix materials and morphogenetic roteins, wherein depending on the subject matter the proteins may be dimeric or monomeric proteins. The osteoinductive materials according to the present invention have improved properties. The invention further concerns methods for producing the respective improved osteoinductive materials.06-18-2009
20090155365Method for remotely controlling a sol-gel transition of hydrogels and method for delivering a drug using the same - The present invention relates to a method for remotely controlling a sol-gel transition of hydrogels and a method for delivering a drug using the same. More specifically, the invention relates to a method of remotely controlling a sol-gel transition of polyethylene glycol (PEG)-containing hydrogels—three-dimensional networks of crosslinked polymer chains—by X-ray irradiation, and relates to a method for delivering a drug using the same.06-18-2009
20100104642HYDROPHILIC FOAM AND PHARMACEUTICAL DOSAGE FORM EMPLOYING THE SAME - Disclosed herein is a hydrophilic foam. The hydrophilic foam includes a polyurethane matrix having a plurality of cells. The cells are capable of retaining water in an amount of least about 8 grams of water per gram of the hydrophilic foam.04-29-2010
20080254123Morphine polymer release system - A pharmaceutical composition for controlled release of an active substance is provided. The active substance is released into an aqueous medium by erosion of at least one surface of the composition. The composition comprises i) a matrix comprising a) polymer or a mixture of polymers, b) an active substance and, optionally, c) one or more pharmaceutically acceptable excipients, and ii) a coating.10-16-2008
20100124570HIGHLY RESILIENT COPOLYMER WITH SHAPE RECOVERY FORCE AND FLEXIBILITY AND THE USE THEREOF FOR THE REPAIR OF ARTICULAR CARTILAGE DEFECTS - The present invention relates to a highly resilient (lactide/glycolide)/ε-caprolactone copolymer with good shape recovery force, flexibility, and biodegradability and a use of such copolymer for the repair of articular cartilage defects. The highly resilient (lactide/glycolide)/ε-caprolactone copolymer of the present invention is capable of rapidly and efficiently inducing cartilage regeneration, can be easily deformed and almost completely restored to its original form after deformation. Further, the highly resilient copolymer of the present invention can be safely and conveniently transplanted to a patient by using an arthroscope without causing economic, physical, and mental burden. Thus, the highly resilient copolymer of the present invention can be effectively used as a polymer scaffold for the repair of cartilage defects.05-20-2010
20090041845Implantable medical devices having thin absorbable coatings - Disclosed herein is a coating having a layer that includes a matrix phase and a dispersed phase substantially immiscible in the matrix phase and methods of using the same.02-12-2009
20110008440NOVEL NANOCOMPOUND MATERIALS WITH INFRARED, ULTRAVIOLET AND VISIBLE ELECTROMAGNETIC RADIATION BLOCKING PROPERTIES AND METHOD FOR OBTAINING THEM - The present invention refers to novel nanocomposite materials with protection properties against infrared and ultraviolet-visible radiation, to the method for obtaining them, which comprises the stages of reducing the size of the laminar particles by mechanical action, filtering, removing organic matter, removing crystalline oxides and hard particles that are not subject to modification, obtaining laminar fines or laminar structure, pre-treating laminar structures by means of precursors, and adding the product resulting from the previous stages in liquid or dry state to a plastic matrix. The invention also refers to the use of said materials for different industry fields.01-13-2011
20090297607BIOMIMETIC POLYMERS AND USES THEREOF - Biodegradable polymers incorporating biomolecules and methods of their use are provided. Certain aspects provide biomolecules crosslinked with diglycidyl esters. The disclosed compositions have numerous applications including cellular regeneration, wound healing, and cellular differentiation.12-03-2009
20090074868PHOTOINITIATED TISSUE FILLER - Visible light-activated polymer cosmetic filler preparations useful in a variety of applications are provided. In some embodiments, the photo-activated polymer composition comprises a conventional polymeric material, such as HA, together with a modified, cross-linkable polymer, such as PEG or PEODA, to permit the formation of crosslinks within the polymer matrix in situ on exposure to a visible light source, such as an IPL device. The preparations provide for a more stabilized composition that is contourable during gelation.03-19-2009
20130129826TAMPER-RESISTANT ORAL PHARMACEUTICAL DOSAGE FORM COMPRISING OPIOID ANTAGONIST AND/OR AVERSIVE AGENT, POLYALKYLENE OXIDE AND ANIONIC POLYMER - The invention relates to a pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising (i) a pharmacologically active ingredient; (ii) an opioid antagonist and/or an aversive agent; (iii) a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol; and (a) further comprising (iv) an anionic polymer; and/or (b) having a storage stability at 40° C. of at least 3 months.05-23-2013
20090238874BIOMIMETIC COMPOSITION REINFORCED BY A POLYELECTROLYTIC COMPLEX OF HYALURONIC ACID AND CHITOSAN - The present invention relates to a three dimensional, malleable cell culture composition and method of forming the same comprising hyaluronic acid, chitosan and a polyelectrolytic complex of hyaluronic acid and chitosan. These three components in combination constitute an initial microenvironment for support of stromal cells, and their undifferentiated mesenchymal cell progeny. The tissue engineering device and method of forming the same comprising hyaluronic acid and chitosan and the use of said device with compositions of pluripotent cells and various formulations of cell culture media for repair of tissues is disclosed.09-24-2009
20090232891Cell Transport Compositions and Uses Thereof - Compositions and methods have been developed for transporting compounds across membranes with little or no toxicity and, when targeted through the appropriate routes of administration (i.e., lung, gastrointestinal (GI) tract), little or no immune stimulation. The compositions can mediate cellular delivery of compounds that would otherwise not enter cells and enhance the intracellular delivery of compounds that would otherwise enter cells inefficiently. The methods are carried out by contacting a proximal face of a lipid bilayer or membrane (e.g. the surface of an intact cell) with a complex containing a compound (e.g., a therapeutic agent) and a diketopiperazine (DKP). DKP and the compound are non-covalently associated with each other or covalently bound to each other.09-17-2009
20090047349DRUG DELIVERY DEVICE - Drug delivery devices are provided herein including crosslinked polymeric compositions. The devices may, in embodiments, possess at least two drug release profiles, in embodiments at least three drug release profiles.02-19-2009
20090047348POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF - A biodegradable and thermosensitive poly(organophosphazene) with a functional group, a preparation method thereof, and a use thereof for delivery of bioactive substances are provided.02-19-2009
20120114755METHODS AND MATERIALS FOR TISSUE REPAIR - This document relates to methods and materials for treating tendon injury. Specifically, methods and materials for preventing adhesion formation and promoting tissue healing following tendon injury and surgical repair are provided.05-10-2012
20090022805Polypeptide microparticles having sustained release characteristics, methods and uses - The invention provides polypeptide microparticles having control release features, particular methods for the preparation of such microparticles, and drug delivery systems that include polypeptide microparticles.01-22-2009
20090011028Self-precipitating pharmaceutical formulations for the moified release of an active principle - The present invention relates to novel pharmaceutical formulations for the release of an active principle (AP) over a sustained period of time of several days, or even several weeks.01-08-2009
20090011027Modifying Drug Release in Suspensions of Ionic Resin Systems - The present invention includes compositions and methods for delivering one or more unit dosage units by modifying the release profile of an optionally coated drug-resin complex suspended in an ionic salt solution, wherein the optionally coated drug-resin complex includes one or more active agents loaded on to one or more ion-exchange resin particles, and wherein the release of the one or more active agents is modulated by the one or more ionic salts in solution.01-08-2009
20090011026TRANSCORNEAL SYSTEM FOR DELIVERY OF A PHARMACEUTICAL AGENT - The invention relates to a transcorneal system for delivery of a pharmaceutical agent, made from a matrix material forming a baseplate (01-08-2009
20090011025Biotin-Amino Acid Conjugate Useful as a Hydrogelator and Hydrogel Prepared Therefrom - A biotin-amino acid conjugate, wherein the carboxylic group of biotin and the α-amino group of an amino acid is linked by an amide bond, is biocompatible and has an excellent gelation capability in an aqueous medium. Accordingly, a hydrogel prepared therefrom is useful as a drug delivery system.01-08-2009
20110123621HYDROGEL WOUND DRESSING AND BIOMATERIALS FORMED IN SITU AND THEIR USES - The present invention relates to a method of forming shape-retentive and shape-conforming aggregate wound dressings and biomaterials composed of gel nanoparticles and wound or bodily fluid in which the aggregates are held together by non-covalent bond physical forces such as, without limitation, hydrophobic-hydrophilic interactions and hydrogen bonds. The method comprises introducing a dry powder of gel nanoparticles to a wound site in which the nanoparticles absorb some of the blood or wound exudate and coalesce in situ into the claimed shape-retentive aggregate dressing. The method also comprises introducing the dry nanoparticle powder in or on a wet bodily tissue in vivo to form the claimed shape-retentive biomaterial. In addition, the method also comprises incorporating biomedical agents to produce medicated aggregate dressings or biomaterials for a variety of medical applications. This invention also relates to uses of the method of formation of the shape-retentive aggregates of gel nanoparticles.05-26-2011
20090311325ENHANCING SOLUBILITY AND DISSOLUTION RATE OF POORLY SOLUBLE DRUGS - The present invention relates generally to use of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR, in the formulation of solid dispersions of low aqueous solubility and dissolution rate bioactive compound and, more particularly to a system and method for improving the solubility and dissolution rate of such low aqueous solubility and dissolution rate bioactive compound, in particular the drug of low aqueous solubility, such as a BCS Class II or Class IV drug compounds.12-17-2009
20110097407Butenafine Hydrochloride-Containing Aqueous Patch - Disclosed is a water-based adhesive skin patch which has excellent storage stability, can achieve excellent accumulation of butenafine hydrochloride contained therein on a patched area such as the skin and a nail, and has a high therapeutic effect. Specifically disclosed is a water-based adhesive skin patch containing butenafine hydrochloride, which is characterized by containing butenafine hydrochloride, glycol salicylate and propylene glycol in a water-containing gel ointment. Specifically, butenafine hydrochloride is dissolved in a mixed solution of glycol salicylate and propylene glycol, and the resulting solution is dispersed in a water-containing gel. Particularly, the mixing ratio of glycol salicylate to propylene glycol is 1:2 to 1:30.04-28-2011
20110008442Dendritic Macroporous Hydrogels Prepared by Crystal Templating - The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel.01-13-2011
20090110731Loadable Polymeric Microparticles for Therapeutic Use in Alopecia and Methods of Preparing and Using the Same - Particles are provided for use in restorative procedures to treat and/or retard alopecia The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in various colors or with customized coloration to match desired scalp colors. Moreover, such particles may be loaded to provide localized treatment with an active component agent directed at restoration of normal function and hair production within the hair follicle.04-30-2009
20090285896BIOABSORBABLE POLYESTERAMIDES AND USES THEREOF - Novel biodegradable polyesteramides derived from optionally functionalized diacids and optionally functionalized diamines or from compounds having both optionally functionalized acid and optionally functionalized amine moieties, their preparation, and absorbable surgical articles fabricated therefrom, such as monofilament and multifilament sutures, films, sheets, plates, clips, staples, pins, screws, stents, stent coatings, packaging materials, and other implantable surgical devices, and the like, are described herein.11-19-2009
20090280182Devices for the treatment of wounds and methods and kits therefor - Interpenetrating network hydrogels are described that may be incorporated into wound dressings and/or in implants. The properties of the interpenetrating network hydrogel may be tuned to control an amount of moisture in a wound environment. The devices, methods, and kits described herein may be adapted to treat a variety of wound types at a variety of healing stages over a range of time scales. Some hydrogels may be configured to deliver one or more vulnerary agents to a wound. The interpenetrating network hydrogels may also be adapted to control a rate and/or amount of moisture uptake so that the hydrogels may be used as expandable implants to expand tissue.11-12-2009
20100034883Light-curable bone growth material for treating dental bone defects - Improved compositions comprising a mixture of particulate bone growth material and polymeric carrier are provided. The particulate is preferably porous, resorbable, anorganic bone material. The polymeric carrier can be light-cured to form a cross-linked, biodegradable hydrogel. In one version, the bone growth material is a synthetic peptide bound to anorganic bone matrix particles and the carrier is methacrylated sodium hyaluronate (MHy) or methacrylated hydroxyethylcellulose (MHEC). The composition is particularly suitable for repairing defective dental and orthopedic bone tissue. The particulate and hydrogel carrier are biodegradable so the composition can be replaced by new bone formation over time.02-11-2010
20100034882SILVER-CONTAINING COMPOSITIONS, DEVICES AND METHODS FOR MAKING - The present invention comprises methods and compositions for making a silver-containing antimicrobial hydrophilic material. More particularly, the present invention comprises methods and compositions for stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide, and an active agent. The matrix may be formed into any desired shape for its desired uses.02-11-2010
20110217379MAGNETIC NANOMATERIALS AND METHODS FOR CHEMOEMBOLISATION - There are disclosed magnetic nanoparticles and embolisation compositions comprising the nanoparticles. There are also disclosed methods to make the nanoparticles and embolisation compositions and methods to deliver therapeutic agents to a subject.09-08-2011
20090148528Material that progressively liberates an active liquid substance by evaporation, and mosquito repellent bracelet incorporating such a material - A material controllingly releases by evaporation a liquid active substance and comprises a polymer material matrix impregnated with a liquid composition. The liquid composition contains a mixture of the active substance and a solute which reduces the active substance evaporation kinetics by decreasing a vapor pressure. A method for producing the material and an accessory comprising an element made therefrom are also described.06-11-2009
20090148529Hydrogel Suspension and Manufacturing Process Thereof - The present invention relates to a hydrogel suspension which comprises a fine particle and high molecular weight hydroxypropylmethyl cellulose or methylcellulose, which exhibits high transparency and stability; and a manufacturing process thereof.06-11-2009
20080268057Controlled release carvedilol compositions - A controlled release pharmaceutical composition for oral use comprising carvedilol. The composition releases carvedilol after oral administration to a mammal, including a human, in such a manner that a prolonged residence of carvedilol is obtained in the circulatory system compared with the known compositions of carvedilol. Furthermore, a composition according to the present invention makes available to the body a suitable plasma concentration of one or both of the enantiomeric species, namely R(+) and/or S(−) carvedilol for obtaining the desired therapeutic effect.10-30-2008
20110212178Injectable Hydrogel Filaments For Biomedical Uses - Described herein are apparatus, compositions, systems and associated methods to occlude structures and malformations with radiopaque hydrogel filaments with delayed controlled rates of expansion permitting the repositioning of the device once inside the structure or malformation. Further described is a device for implantation in an animal comprising a difunctional, low molecular weight ethylenically unsaturated shapeable macromer; an ethylenically unsaturated monomer; and a radiopaque element, wherein said device contains no support members. Methods of forming such devices are also disclosed.09-01-2011
20100086596MICROSPHERES FOR RELEASING AN OCTREOTIDE COMPOUND WITHOUT AN INITIAL TIME LAG - Microspheres for releasing an octreotide compound without an initial time lag include a poly(D,L-lactide-co-glycolide) polymer (PLGA polymer) matrix having a ratio of lactide to glycolide ranging from 80:20 to 90:10 mol %. The polymer has a molecular weight ranging from about 6000 to 16000. The octreotide compound is dispersed in the polymer matrix. The microspheres can be made by forming a dispersed phase by combining the above polymer, dichloromethane, the octreotide compound, methanol and acetic acid. A target loading of the octreotide compound in the dispersed phase ranges from 7 to 12% by weight. Polyvinyl alcohol is dissolved in water to form a continuous phase. The dispersed phase is mixed in the continuous phase to form a microsphere suspension. The dichloromethane, acetic acid, methanol and polyvinyl alcohol are removed from the microsphere suspension. Residual dichloromethane and methanol are removed from the microspheres by washing.04-08-2010
20100086598TRAVERSAL OF NUCLEIC ACID MOLECULES THROUGH A FLUID SPACE AND EXPRESSION IN REPAIR CELLS - Disclosed are methods for use in transferring nucleic acids into cells at a wound site associated with a fluid space. These gene transfer protocols are suitable for use in transferring various nucleic acids into cartilage, cardiac muscle, and other tissues, and have many uses including treating diseases such as arthritis and ischemic heart disease, and promoting wound healing. The invention further disclosed pharmaceutical compositions that may be used in the practice of the invention to transfer the nucleic acid of interest. Such compositions include any multi-partitioned biocompatible matrix in combination with multiple nucleic acids of interest.04-08-2010
20120107404Crystalline Pharmaceutical and Methods of Preparation and Use Thereof - Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.05-03-2012
20090263484Tissue Engineering Devices and Methods for Luminal Organs - Tissue engineering devices and methods are provided for the reconstruction, repair, augmentation, or replacement of a luminal organ or tissue structure involving the use of a biodegradable polymer matrix conforming to a portion of a laminarly arranged luminal organ, the processing of autologous, allogeneic or xenogeneic tissue comprising multiple cell populations to obtain a minced tissue composition, the seeding of the matrix with the composition, and the implanting of the seeded polymer matrix into a patient.10-22-2009
20100098761Polymer Compositions For Biomedical And Material Applications - The invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement. In further embodiments, the materials contain polyhedral silsesquioxanes and/or biodegradable segments. In further embodiments, the polymer matrix comprises biomolecules.04-22-2010
20090047350Perforated water soluble polymer based edible films - A novel edible polymer based film dosage form manufactured using natural, synthetic, semisynthetic, pharmaceutically acceptable polymers addressing the issues of swallowing difficulties (Dysphagia and Dynaphagia), of tablet or capsule dosage forms and handling and storage difficulties associated with liquid dosage forms, that also includes materials such as emulsifying agents, suspending agents, buffering agents, effervescence agents, colorants, flavorants, sweetners and specified amounts of bioactive agents preferably having perforations in the body of the dosage form enabling it to disperse/dissolve rapidly upon application by the subject. A flexible film dosage form to accommodate higher drug loads without compromising the fast dispersing/dissolving characteristics is presented. The perforated film system is enabled to be used in various applications such as oral, mucosal and external environments. The perforated film dosage form therefore, additionally allows the usage of polymers that would otherwise have not been used due to insolubility or limited solubility in water.02-19-2009
20080274190TEMPERATURE AND pH - SENSITIVE BLOCK COPOLYMER HAVING EXCELLENT GEL STRENGTH, METHOD OF PREPARING THE SAME, AND DRUG DELIVERY SYSTEM USING THE SAME - Disclosed herein is a temperature- and pH-sensitive block copolymer having excellent gel strength, including: (a) a poly(ethylene glycol)-based compound (A) or a copolymer (B) of the poly(ethylene glycol)-based compound (A) and a biodegradable polymer; and (b) a polyurethane-based oligomer (C). Further, a method of preparing a temperature and pH-sensitive block copolymer having excellent gel strength, including: (a) synthesizing a poly(ethylene glycol)-based compound (A) or a copolymer (B) of the poly(ethylene glycol)-based compound (A) and a biodegradable polymer; and (b) coupling a polyurethane-based oligomer (C) with the copolymer (B), is disclosed. Also disclosed is a polymer hydrogel type drug delivery system, including: (a) the block copolymer; and (b) a physiologically active substance which can be included in the block copolymer.11-06-2008
20090285895Pharmaceutical Formulation for Regulating the Timed Release of Biologically Active Compounds Based on a Polymer Matrix - A formulation containing a biologically active compound having a structure with hydrogen bonding sites is blended with a polymer having a structure with complementary hydrogen bonding sites, the polymer forming hydrolytic degradation products that promote the release of the biologically active compound from the polymer.11-19-2009
20080206337METHOD OF MAKING DOSAGE FORMS COMPRISING POLYMERIC COMPOSITIONS - A dosage form comprises: (a) at least one active ingredient; (b) a core having an outer surface; and (c) a shell which resides upon at least a portion of the core outer surface, wherein at least a portion of the shell is semipermeable, such that the liquid medium diffuses through the semipermeable shell or shell portion to the core due to osmosis. The shell also provides for delivery of the active ingredient to a liquid medium outside the shell after contacting of the dosage form with the liquid medium. The dosage form delivers one or more active ingredients in a controlled manner upon contacting of the dosage form with a liquid medium. The dosage form may be employed to provide a burst release of the active ingredient, or to provide release of the active ingredient at an ascending release rate over an extended time period upon contacting of the dosage form with a liquid medium. At least a portion of the shell may be comprised of a polymeric composition containing film former, gelling agents, which can be dissolved in a multisolvent system comprised of water and an organic solvent.08-28-2008
20090285894MICRO-PARTICLES CONTAINING A 3-D POLYMERIC STRUCTURE - Micro-sized particles having a polymeric structure of cells are provided. Also provided is a method of producing micro-sized particles having a polymeric structure comprising: (1) forming a homogenous solution by heating a mixture of a high molecular weight polymer and a low molecular weight material, wherein said low molecular weight material makes up at least about 50% by weight of the homogenous solution, (2) forming a dispersed solution by dispersing the homogenous solution formed in step (1) into an inert material, (3) cooling the dispersed solution to cause the high molecular weight polymer to phase separate from the low molecular weight material, (4) forming solid particles comprised of said low molecular weight material trapped inside a structure of cells of said high molecular weight polymer, and (5) removing the solid particles from the dispersed solution.11-19-2009
20110200674ANTIMICROBIAL FOAM AND METHOD OF MANUFACTURE - An antimicrobial foam includes an open-cell foam in a foam matrix defining a plurality of interconnected bubbles therein. Silver nanoparticles are suspended within the foam matrix. The foam matrix may be made from polyether polyurethane, polyester polyurethane, polycarbonate, thermoplastic olefin, thermoplastic elastomer, and thermoplastic polyurethane. The silver nanoparticles may have an average size between about 5 and 100 nanometers. The silver nanoparticles may be incorporated into the foam matrix in a concentration of between about 0.01 weight-% and about 0.20 weight-%. A method of manufacture of the foam also is described.08-18-2011
20120294944SUSTAINED-RELEASE NUCLEIC ACID MATRIX COMPOSITIONS - The present invention provides compositions for extended release of a nucleic acid agent, a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the nucleic acid agent.11-22-2012
20080213371Rapidly disintegrating solid oral dosage form - Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.09-04-2008
20100136114DE NOVO FORMATION AND REGENERATION OF VASCULARIZED TISSUE FROM TISSUE PROGENITOR CELLS AND VASCULAR PROGENTITOR CELLS - It has been discovered that vascularized tissue or organs can be engineered by combined actions of tissue progenitor cells and vascular progenitor cells. Provided herein are compositions and methods directed to engineered vascularized tissue or organs formed by introducing tissue progenitor cells and vascular progenitor into or onto a biocompatible scaffold of matrix material. Also provided are methods of treating tissue defects via grafting of such compositions into subjects in need thereof.06-03-2010
20080241247Compositions and Methods To Control the Growth Of Microorganisms In Aqueous Systems - Compositions and methods for killing, preventing, or inhibiting the growth of microorganisms in an aqueous system or other systems are provided. The compositions can include at least one first cross-linkable polymer, at least one second cross-linkable polymer, and at least one cross-linking agent, wherein the water solubilities of each cross-linking polymer are different, such as by 10% to 100%. The compositions can further include at least one biocidal component. The compositions can be formulated to slowly release the biocidal component and/or the cross-linkable polymer, or rapidly release the biocidal component and slowly release the cross-linkable polymer. The compositions can be used to control algae.10-02-2008
20080241248Porous Matrix - A porous matrix suitable for use as a tissue scaffold is described. The matrix may be shaped before insertion into or at the target tissue site, or injected via a minimally invasive method. The matrix may be pre-seeded with cells of the target tissue or may be used to support growth of the local endogenous tissue. The matrix may contain growth factors or other pharmacologically acceptable moieties such as antibiotics.10-02-2008
20100129450Electrospun Cell Matrices - The invention is directed to compositions and methods for preparing electrospun matrices comprising at least one natural biological material component and at least one synthetic polymer material. The natural component makes the matrices highly biocompatible while the molecular weight polymer component can impart additional strength mechanical strength to the scaffold and/or improve ease of manufacture by increasing viscosity and spinning characteristics of the solution during electrospining.05-27-2010
20090246280Resin Powder Containing Aluminum Salt, Process for Production of the Same, and Resin Composition, Phosphorus Adsorbent, Antibacterial Agent or Antifungal Agent Comprising the Same - An aluminum salt-containing resin powder of the present invention includes: at lest one matrix resin component selected from regenerated collagen, polyvinyl alcohol and carboxymethyl cellulose; and an aluminum salt. The aluminum salt is chemically bonded to the matrix resin component, and the resultant is powdered. A resin composition of the present invention includes 0.1 wt % or more and 80 wt % or less of the aluminum salt-containing resin powder and 20 wt % or more and 99.9 wt % or less of a resin other than the aluminum salt-containing resin. Thus, the present invention provides an aluminum salt-containing resin powder having a high phosphorus adsorption property, a high antibacterial property and a high antifungal property, and a resin composition containing the aluminum salt-containing resin powder.10-01-2009
20100209509BIFUNCTIONAL-MODIFIED HYDROGELS - Disclosed are hydrogels wherein a polymer matrix is modified to contain a bifunctional poly(alkylene glycol) molecule covalently bonded to the polymer matrix. The hydrogels can be cross-linked using, for example, glutaraldehyde. The hydrogels may also be crosslinked via an interpenetrating network of a photopolymerizable acrylates. The hydrogels may also be modified to have pharmacologically-active agents covalently bonded to the poly(alkylene glycol) molecules or entrained within the hydrogel. Living cells may also be entrained within the hydrogels.08-19-2010
20080279944Composite hydrogel drug delivery systems - Compositions and methods are provided to control the release of relatively low molecular weight therapeutic species through hydrogels by first dispersing or dissolving such therapeutic species within relatively hydrophobic rate modifying agents to form a mixture. The mixture is formed into microparticles that are dispersed within bioabsorbable hydrogels, so as to release the water soluble therapeutic agents in a controlled fashion. Methods of using the compositions of the present invention in therapeutic systems are also provided.11-13-2008
20080292707Pharmaceutical Compositions of Adsorbates of Amorphous Drug - Pharmaceutical compositions comprise a low-solubility drug adsorbed onto a high surface area substrate to form an adsorbate. The compositions in some embodiments include a concentration-enhancing polymer.11-27-2008
20080292706Hydrogel composition and methods for making the same - The invention provides a hydrogel composition comprising water and a hydrophilic polymer, wherein the hydrogel composition has (a) an ultimate tensile strength of about 10 kPa or more, (b) a compressive strength of about 70 kPa or more, or (c) an ultimate tensile strength of about 10 kPa or more and a compressive strength of about 70 kPa or more. The invention further provides methods for producing a hydrogel composition.11-27-2008
20100291214THREE-DIMENSIONAL MICROFIBER EXTRUDATE STRUCTURE AND PROCESS FOR FORMING THREE-DIMENSIONAL MICROFIBER EXTRUDATE STRUCTURE - Disclosed is a three-dimensional microfiber extrudate structure and a process of forming a three-dimensional microfiber extrudate structure. The three-dimensional microfiber extrudate structure includes a matrix having a three-dimensional geometry wherein the three-dimensional geometry is a visco-elastic relaxation state of a preform introduced to a medium.11-18-2010
20090004273Polymeric device for controlled release of active agents - Polymeric devices for controlled release of an active agent of interest are provided. The active agent is provided within a biodegradable polymer system to supply a polymeric device for controlled release of the active agent. The polymer system is a copolymer or a polymer blend comprising a hydrophobic component and a hydrophilic component, and the polymer system does not form a hydrogel when contacted with, or immersed in an aqueous system, for example when the device is implanted in a subject. When the device is administered to a subject, for example, when it is implanted, the device releases the active agent in a controlled fashion without a lag period, or with a minimal lag period. Methods for producing the polymeric devices are also provided, as are methods of using the polymeric devices to provide for controlled release of an active agent in a subject.01-01-2009
20090004271Morselized foam for wound treatment - A wound treatment material comprising morselized foam is described. The morselized foam comprises a biocompatible, biodegradeable polymer. Methods for wound treatment and/or repair and/or regeneration of tissue using morselized foam are disclosed.01-01-2009
20100003327Bioabsorbable Polymeric Composition for a Medical Device - A biodegradable and biocompatible nontoxic polymeric composition is provided which includes a base material such as a crystallizable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive. Medical devices manufactured from the composition are also provided.01-07-2010
20090004274Hydrogen Bonded Hydrogels - The present invention relates to new hydrogel materials using water gellants that are comprised by hydrophilic polymers to which hydrogen bonding units are covalently attached. Optionally, the hydrogel contains additional ingredients or additives. These new reversible hydrogels can easily be fine-tuned in their mechanical performance and functionality and are especially suitable for cosmetic and biomedical applications.01-01-2009
20090004272Polymeric devices for controlled release of active agents - Polymeric devices for controlled release of an active agent of interest are provided. The active agent is provided within a biodegradable polymer system to supply a polymeric device for controlled release of the active agent. The polymer system is a copolymer or a polymer blend comprising a hydrophobic component and a hydrophilic component, and the polymer system does not form a hydrogel when contacted with, or immersed in an aqueous system, for example when the device is implanted in a subject. When the device is administered to a subject, for example, when it is implanted, the device releases the active agent in a controlled fashion without a lag period, or with a minimal lag period. Methods for producing the polymeric devices are also provided, as are methods of using the polymeric devices to provide for controlled release of an active agent in a subject.01-01-2009
20090208578Method of tissue repair using a multi-layered matrix - A multi-layered matrix, a method of tissue repair using the same, and multi-layered implant prepared thereof are provided. The multi-layered matrix comprises a first element and a second element connected thereto, and the second element comprises a hollow cavity. The first and the second elements are composed of a composite material comprising a bioabsorbable porous material.08-20-2009
20090324721Hydrogels Suitable For Use In Polyp Removal - Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic functional groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable, or not, are provided, as are methods for controlling the rate of degradation. The crosslinking reactions may be carried out in situ on organs or tissues or outside the body. In embodiments, the biocompatible crosslinked polymers and/or their precursors may be utilized in a surgical procedure, such as a polypectomy.12-31-2009
20090081294Sustained release dosage form for lubricating an oral cavity - Aspects of the invention include a sustained release dosage form that can be administered to an oral cavity, e.g., the mouth. In certain embodiments, the sustained release dosage form is formulated as a lozenge or gum that may be administered to an oral cavity for the purpose of providing lubrication therein. In certain embodiments, the sustained release dosage form not only provides lubrication to a mucosal surface of an oral cavity, but also provides for the sustained release of a flavoring and/or beneficial agent. Accordingly, in certain embodiments, the sustained release dosage form includes a water-insoluble polymer, e.g., ethylcellulose, an essential oil component, and an effective amount of a film forming binder, e.g., xanthan gum. In certain embodiments, the effective amount of the film forming binder and the type of film forming binder are selected so as to provide the sustained release dosage with the capability of lubricating one or more mucosal surfaces within an oral cavity when the dosage form is positioned therein. In certain embodiments, the sustained release dosage form is formulated in a manner sufficient to form a matrix that includes the various components of the sustained release dosage form, such that when positioned in an oral cavity the matrix slowly dissolves and thereby lubricates the oral cavity and/or delivers a flavoring and/or beneficial agent thereto. Methods of formulating such dosage forms and administering them to an oral cavity for the treatment of an adverse condition are also provided.03-26-2009
20080268056INJECTABLE COPOLYMER HYDROGEL USEFUL FOR REPAIRING VERTEBRAL COMPRESSION FRACTURES - Embodiments of the present invention provide a biocompatible substance useful for repairing a vertebral compression fracture (VCF). The biocompatible substance can be made from two or more biocompatible polymeric hydrogels via physical cross-linking. The biocompatible substance thus made exhibits a lower critical solution temperature (LCST) phenomenon and undergoes volume and stage changes with temperature in the range of 25° C.-34° C. The biocompatible substance can be in liquid injectable form at room temperature, can cure within the human body without damaging living tissues, does not release toxic monomers during surgery, and, once cured, has optimum mechanical properties that match those of a human cancellous bone. It can be used alone in minimally invasive procedures or in combination with other spine treatments.10-30-2008
20090220606TREATMENT AND PREVENTION OF ABNORMAL CELLULAR PROLIFERATION - This invention provides a method for inhibiting or preventing the abnormal growth of cells, including transformed cells, by administering an effective amount of O-acylated heparin derivative. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanism (e.g. loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors); (2) benign and malignant cells of other proliferative disease in which aberrant cellular proliferation occurs; (3) aberrant smooth muscle cell proliferation, such as might occur following treatment for coronary atherosclerosis such as angioplasty or the insertion of a stent into an occluded vessel.09-03-2009
20090220605BONE MATRIX COMPOSITIONS HAVING NANOSCALE TEXTURED SURFACES - Bone matrix compositions having nanoscale textured surfaces and methods for their production are provided. In some embodiments, bone matrix is prepared for implantation and retains nanoscale textured surfaces. In other embodiments, nanostructures are imparted to bone matrix wherein collagen fibrils on the surface of the bone matrix have been compromised, thus imparting a nanoscale textured surface to the bone matrix. Generally, these methods may be applied to mineralized or demineralized bone including partially or surface demineralized bone.09-03-2009
20090220604AMINO ACIDS IN MICELLE PREPARATION - Formulations are formed of a diblock copolymer (X—Y) having a hydrophilic block X comprising residues of monomer x, and a hydrophobic block Y comprising residues of monomer y; an additive selected from an amino acid and an oligopeptide. Upon admixture with water, the formulations form drug delivery vehicles, preferably in micellar form. The inclusion of amino acid and/or oligopeptide provides for the formation of micelles at an enhanced rate, and/or provides the formation of micelles having an enhanced ability to incorporate drug(s), and/or provides the formation of micelles having advantageous physical characteristics.09-03-2009
20090246279PARTICLES HAVING HYDROPHOBIC MATERIAL THEREIN - A process for preparing particles having a hydrophobic material therein is disclosed. The process comprises providing a multiple emulsion comprising a first emulsion dispersed in a hydrophobic medium, said first emulsion comprising a hydrophobic phase dispersed in a hydrophilic phase, wherein the hydrophobic phase comprises the hydrophobic material and the hydrophilic phase comprises a precursor which is capable of reacting to form a non-fluid matrix and reacting the precursor in the multiple emulsion to form the matrix in the form of the particles having the hydrophobic material therein wherein the precursor is added prior to formation of the multiple emulsion. Also disclosed are particles having a hydrophobic material therein, which may be releasable, as well as particles having a hydrophobic material therein, which may be releasable, made by the process and methods of using the particles.10-01-2009
20090117190SUSTAINED-RELEASE PREPARATION - It is intended to provide a sustained-release pharmaceutical preparation with absorbability not dependent on pH. The sustained-release preparation is characterized by containing 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone or a salt thereof, as a pharmaceutically active ingredient, and containing a hydrogel base and an organic acid.05-07-2009
20100260848SYSTEM FOR CONTROLLED RELEASE OF AN ACTIVE PRINCIPLE AND METHOD FOR PREPARATION - A system for controlled release of an active principle, includes at least (a) a degradable polymer matrix which produces acid compounds and (b) at least one acid-sensitive complex of an active principle having at least one electrostatic charge and a complexing polyelectrolyte partner of opposite charge which complexes with the active principle. A method for preparation of such a system is described. The release of the active principle (7P) is prolonged over 18 days (ternary system PMLA/7P/PLAGA) in comparison to binary systems (7P/PLAGA) and (PMLA/7P).10-14-2010
20100260849REMINERALIZING COMPOSITIONS AND METHODS - The present application provides compositions comprising a divalent metal cation source or divalent metal cations dissolved in a substantially anhydrous liquid, and methods of making and using the compositions. Such compositions can be useful for remineralizing dental structures and/or providing other useful effects including an anticaries effect.10-14-2010
20100226986Therapeutic Particles Suitable for Parenteral Administration and Methods of Making and Using Same - Disclosed herein are therapeutic compositions for treating and preventing diseases such as neointimal hyperplasia (NIH), where the compositions comprise a therapeutic particle that has a localized association with a blood vessel and a therapeutic agent, such as an anti-NIH agent. Methods of use of the therapeutic compositions are also disclosed.09-09-2010
20100255098STEREOCOMPLEX HYDROGELS - The invention relates to hydrogel compositions, which can be applied as biodegradable materials and to the processes to prepare such hydrogels. The hydrogel of the present invention comprises a stereocomplex gel structure which is the result of the interaction of oligomerized monomers of one chirality with that of oligomerized monomers of the opposite chirality, both grafted to hydrophilic polymers. The grafts form an interaction which is different from a covalent chemical interaction and thus provide the gel with the required coherence.10-07-2010
20110059175ENHANCING SOLUBILITY AND DISSOLUTION RATE OF POORLY SOLUBLE DRUGS - The present invention relates generally to use of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR, in the formulation of solid dispersions of low aqueous solubility and dissolution rate bioactive compound and, more particularly to a system and method for improving the solubility and dissolution rate of such low aqueous solubility and dissolution rate bioactive compound, in particular the drug of low aqueous solubility, such as a BCS Class II or Class IV drug compounds.03-10-2011
20100226985VISCOELASTIC AQUEOUS GELS COMPRISING MICROSPHERES - The present invention provides viscoelastic gel compositions comprising microparticles which are capable of interacting with each other in a non-ionic manner, thus forming a gel network. The gel compositions may incorporate active agents and provide controlled release of such agents. The compositions are useful as injectable depot formulations of therapeutic compounds. In a further aspect, microparticles capable of gel formation in an aqueous environment are provided, as well as method of making viscoelastic gels based on the interaction of uncharged microparticles. Moreover, the invention discloses kits for making viscoelastic gel compositions and uses thereof.09-09-2010
20090074869PHARMACEUTICAL FORMULATIONS - Disclosed are pharmaceutically acceptable PDE V inhibitor Formulations that are especially useful for treating male erectile and female sexual dysfunction and other physiological disorders.03-19-2009
20090022803Oral Formulations For Delivery of Catecholic Butanes Including Ndga Compounds - The present invention provides for compositions, kits and methods for treatment of diseases, where the compositions contain catecholic butanes, including NDGA compounds, such as NDGA derivatives, for example tetra-O-methyl NDGA. The present invention also provides for solubilizing agents and excipients that are suitable for administration of the present compounds into animals via an oral route, whether in a liquid, semi-solid or solid form.01-22-2009
20090110733DELIVERY MEANS - A delivery means for delivering a deliverable material to a wound bed comprises a hydrogel (preferably an optionally cross-linked polyvinylalcohol) and a deliverable material comprising: (i) a decomposable material which in the absence of said hydrogel decomposes and/or is permanently denatured if sterilised using heat, electron beam radiation or gamma radiation; (ii) a protein, protein fragment, peptide or amino acid; or (iii) a secretion or excretion from the organism 04-30-2009
20090110732BIORESORBABLE COMPOSITION FOR REPAIRING SKELETAL TISSUE - Bioresorbable compositions for treating skeletal tissue are disclosed. The biomedical compositions are formed from a polylactide polymer, a polyglycolide polymer, or a poly(lactic-co-glycolic acid) polymer having a relatively low molecular weight. For instance, the average number molecular weight of the polymer is generally less than 10,000, such as from about 500 to about 5,000. Fumarate groups are incorporated into the low molecular weight polymer that provide crosslinking sites. If desired, ethylene oxide groups and ceramic particles may also be incorporated into the polymer for producing compositions having a variety of properties. For example, the biomedical composition of the present disclosure can be used to treat soft skeletal tissue or to treat hard skeletal tissue. The biomedical compositions are biodegradable and can contain various therapeutic, beneficial and pharmaceutical agents that may be released during degradation of the polymer.04-30-2009
20100297237NANOPARTICLES COMPRISING A NON-IONIZABLE POLYMER AND AN AMINE-FUNCTIONALIZED METHACRYLATE COPOLYMER - A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an amine-functionalized methacrylate copolymer.11-25-2010
20100303911Hydrogel systems - A method of in situ hydrogel polymerization is provided. The method comprises combining a backbone polymer with an in situ polymerizable group to form a prepolymer solution which is administered to a target site and polymerized at the target site on exposure to a polymerization-inducing stimulus.12-02-2010
20130136797Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes - An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making the coated complex and the liquid suspension are described.05-30-2013
20100330184INJECTION VEHICLE FOR POLYMER-BASED FORMULATIONS - The invention provides injection vehicles suitable for administering particulate suspensions, such as polymer-based formulations, as well as associated pharmaceutical formulations, articles of manufacture, and kits. Other aspects of the invention included methods for producing and administering pharmaceutical formulations. The injection vehicles of the invention are superior to conventional injection vehicles in that they include a pseudoplastic composition that improves injectability, which facilitates delivery of the desired dose. The injection vehicles of the invention also allow the use of smaller-bore needles than are usually necessary to inject polymer-based formulations, reducing the pain associated with injection of such formulations.12-30-2010
20110008439DULOXETIN COMPOSITION - The present invention relates to a stable pharmaceutical pellet composition comprising duloxetine or a pharmaceutically acceptable salt thereof and a method for making such composition. In particular, the composition comprises duloxetine hydrochloride and a separating layer comprising a water soluble inorganic salt.01-13-2011
20110014289Reticulated Elastomeric Matrices, Their Manufacture and Use in Implantable Devices - This invention relates to biodurable, reticulated elastomeric matrices that are resiliently-compressible, their manufacture and uses including uses for implantable devices into or for topical treatment of patients, such as humans and other animals, for therapeutic, nutritional, or other useful purposes.01-20-2011
20090035377Composition and method for controlling drug delivery from silicone adhesive blends - Compositions and methods for controlling transdermal drug delivery, particularly of amine-functional and basic drugs, comprising a blend of a first silicone-based polymer having a reduced silanol concentration and a second silicone-based polymer have a substantial or high silanol concentration. The blend of such silicone-based polymers, particularly pressure-sensitive silicone adhesives, provides sufficient drug solubility and reduced initial drug delivery onset to permit a prolonged delivery duration at a substantially zero-order rate of delivery.02-05-2009
20100172990BIOCOMPATIBLE MICROGELS AND APPLICATIONS THEREOF - The biocompatible microgels comprises a polymeric network, said polymeric network comprising monomeric units interconnected with one another through a crosslinking agent, wherein said polymeric network can be obtained by polymerization in a dispersed medium of a biocompatible vinyl monomer and a crosslinking agent. The microgel may further comprise a biologically active agent. Said biocompatible microgels can be used, among other applications, to transport and dose biologically active agents.07-08-2010
20110117197SUSTAINED-RELEASE DRUG CARRIER COMPOSITION - The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.05-19-2011
20110151005METHODS AND MEANS FOR SOFT TISSUE ENGINEERING - Cellfree adipose tissue extracts, implants including the same and methods for the preparation thereof. The extracts and implants are capable of inducing adipogenesis and angiogenesis and are, thus, useful in applications including soft tissue repair and engineering and angiogenesis induction, e.g., in wound healing, treatment of burn injuries and ischemic conditions.06-23-2011
20090081295NANOCLUSTERS FOR DELIVERY OF THERAPEUTICS - The present invention discloses a nano-cluster that includes a plurality of nano-particles, wherein the nano-particles can disperse in response to an environmental cue. Also disclosed is a method of preventing, treating, or diagnosing a disease or condition in a subject comprising administering a therapeutically effective amount of a composition comprising nano-clusters of the present invention.03-26-2009
20110091554INJECTABLE COMPOSITE MATERIAL SUITABLE FOR USE AS A BONE SUBSTITUTE - The invention relates to a new injectable composite material suitable for use as a bone substitute. The composite material according to the invention comprises a reactive ceramic phase based on tricalcium phosphate and an organic phase comprising a polyvinyl alcohol hydrogel. By varying the concentration of the two phases it is possible to modulate the mechanical and injectability properties of the material.04-21-2011
20100062066Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration - A pharmaceutical composition for the oral or parenteral administration of a compound of Formula (I) comprising an oil in water emulsion, wherein the oil phase comprises the free base of or a pharmaceutically acceptable salt thereof of a compound of Formula (I), and one or more surfactants which are soluble in the oil phase and/or the aqueous phase. The emulsion optionally contains one or more excipients that are soluble in the oil phase and/or the aqueous phase, such as pH modifying agents such as buffers, osmolality/tonicity modifying agents, emulsifying agents, water-soluble polymers, and preservatives. The compound of Formula (I) can be formulated as a solid material and stored until needed. Kits for forming the emulsion are provided. Prior to administration, the solid material can be reconstituted in an aqueous medium to form the emulsion.03-11-2010
20110104280Wound treatment systems, devices, and methods using biocompatible synthetic hydrogel compositions - A multi-arm poly(ethylene glycol) (PEG) Succinimidyl Glutarate is mixed with a biocompatible, synthetic, nucleophilic polymer component essentially free of human or bovine albumin and other biological molecules, containing, e.g., a polypeptide moiety having a number of active surface lysines of at least twenty (20) per 5000 M/W, which can also be blended with a multi-arm poly(ethylene glycol) (PEG) Amine. The mixture forms a synthetic hydrogel composition. The synthetic hydrogel composition can be applied by topically spraying the synthetic hydrogel composition onto a targeted wound site to promote wound healing.05-05-2011
20090214650Methods of Treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers - The current invention provides methods of treating alcohol related disorders by providing a sustained release oral drug dosage form comprising a plurality of solid state drugs i.e., baclofen and naltrexone, dispersed in a solid state unitary matrix formed from a combination of swellable polymers. The combination of swellable polymers in a single oral drug dosage form is beneficial in terms of release rate control for combination therapies.08-27-2009
20110104281METHOD FOR TREATING PAIN USING A SUBSTITUTED 2-AMINOTETRALIN COMPOUND - A method for treating pain, particularly non-inflammatory musculoskeletal pain such as myofascial pain or back pain, in a subject comprises administering to the subject a substituted 2-aminotetralin compound as defined herein, illustratively rotigotine.05-05-2011
20100297235Vascular puncture closure systems, devices, and methods using biocompatible synthetic hydrogel compositions - A hydrogel composition for application to vascular puncture site of an animal to arrest bleeding and promote hemostasis mixes a biocompatible, synthetic, electrophilic polymer component comprising a poly(ethylene glycol) (PEG) Succinimidyl Glutarate having a functionality of four and a molecular weight of about 10,000 g/mole, with a biocompatible, synthetic, nucleophilic polymer component comprising a blend of a poly(ethylene glycol) (PEG) Amine having a functionality of four and a molecular weight of about 10,000 g/mole, and a Poly-L-Lysine hydrobromide having a molecular weight of greater than about 8000 g/mole.11-25-2010
20100297236HYBRID INDUCIBLE RELEASE VEHICLE - The invention is directed to a hybrid inducible release vehicle, to a method for preparing such a vehicle, and to the use thereof.11-25-2010
20090022804CHEMOEMBOLISATION - A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.01-22-2009
20100086597MICROSPHERES FOR THE SUSTAINED RELEASE OF OCTREOTIDE WITH A LOW INITIAL BURST - This disclosure features microspheres and a method of making them. The microspheres are for sustained release of an octreotide compound with a low initial burst, comprising a poly(D,L-lactide-co-glycolide) polymer matrix and an octreotide compound dispersed in the polymer matrix. The microspheres release less than 1% of a total amount of the octreotide compound within 1 hour at 37° C. and pH 7.4.04-08-2010
20100003326DRUG DELIVERY DEVICE COMPRISING A PHARMACEUTICALLY OR BIOLOGICALLY ACTIVE COMPONENT AND AN INFRARED ABSORBING COMPOUND - The present invention relates to a drug delivery device for implantation in a mammalian body comprising a thermo-sensitive polymeric material, a pharmaceutically or biologically active component and an infrared absorbing compound. The present invention also relates to a method for releasing an active compound from a drug delivery device, the drug delivery device comprising a thermo-sensitive polymeric material, a pharmaceutically or biologically active component and an infrared absorbing compound, wherein the drug delivery device is exposed to infrared irradiation thereby crossing a phase transition.01-07-2010
20090317472CONTROLLED RELEASES OF ACTIVES IN SKIN - Topical compositions are provided in which active compounds for topical delivery through the stratum corneum are complexed with nanospheres of a triblock copolymer having an A-B-A structure wherein each A end block is a water-soluble, hydrophilic and non-toxic polymer or oligomer; and the hydrophobic middle B block is a hydrophobic polymer or oligomer with the same or different repeating units having the structure according to formula:(I) wherein X is —C —R—C— or —C—; Z is between 2 and about 100, inclusive; R12-24-2009
20110151003TRANSDERMAL SYSTEMS CONTAINING MULTILAYER ADHESIVE MATRICES TO MODIFY DRUG DELIVERY - A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix.06-23-2011
20110165248PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(E-CAPROLACTONE) - The present invention relates to pharmaceutical dosage forms, for example to pharmaceutical dosage forms comprising poly(ε-caprolactone), and processes of manufacture, uses, and methods of treatment thereof.07-07-2011
20110165247DEVICE FOR THE TRANSDERMAL ADMINISTRATION OF A ROTIGOTINE BASE - The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine [(−)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphtol], containing a matrix for the transdermal administration of rotigotine [(−)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1 naphtol], containing a matrix polymer which is supersaturated with a rotigotine base. Said polymer matrix is characterised in that the part of the rotigotine which is not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles having a maximum mean diameter of 30 ?m, and the matrix is free of solubilisers, crystallisation inhibitors and dispersants. The invention also relates to a flat device for the transdermal administration of rotigotine, containing the above-mentioned, preferably silicon-based polymer matrix which is supersaturated with rotigotine, and a rear layer which is impermeable to the active ingredient.07-07-2011
20110165246SILICONE ELASTOMER PRODUCT EXHIBITING A BIOCIDAL ACTIVITY - The present invention relates to an antimicrobial product obtained from a silicone-based system exhibiting a biocidal activity on its surface, said system comprising a silicone elastomer matrix and a mineral filler of particles chosen from the group of the silicas or aluminosilicates, for example zeolites or bentonites, said particles being dispersed in said matrix and comprising, grafted to their surface, molecules of the alkylsilane type incorporating at least one quaternary ammonium functional group.07-07-2011
20110020451TAMPER-RESISTANT DOSAGE FORM FOR OXIDATION-SENSITIVE OPIOIDS - Thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, comprising 01-27-2011
20110027368POLYMERIC COMPOSITIONS COMPRISING THERAPEUTIC AGENTS IN CRYSTALLINE PHASES, AND METHODS OF FORMING THE SAME - The present invention relates to a drug-containing polymeric composition comprising at least one therapeutic agent encapsulated in at least one biocompatible polymer, wherein at least a portion of the therapeutic agent in this polymeric composition is crystalline. The at least one biocompatible polymer may form a substantially continuous polymeric matrix with the at least one therapeutic agent encapsulated therein. Alternatively, the at least one biocompatible polymer may form polymeric particles with the at least one therapeutic agent encapsulated therein.02-03-2011
20100285132IMMUNOTHERAPY COMPOSITIONS, METHOD OF MAKING AND METHOD OF USE THEREOF - The present invention directs to compositions and methods for modulating immune system. One aspect of the present invention relates to a composition comprising FADD-dependent signaling pathway modulators. Another aspect of the 5 present invention relates to biodegradable microparticles, such as a chitosan microparticic, or PLGA/PEI microparticle, designed to deliver nucleic acids and/or proteins, such as FADD-dependent signaling pathway modulators, to boost different pathways of an immune response. Another aspect of the present invention relates to the method of making biodegradable microparticles. The further aspect of the present invention relates to the use of the chitosan and other polycationic microparticles to deliver FADD-dependent signaling pathway modulators to modulate immune system for the prevention and/or treatment infectious diseases and cancers.11-11-2010
20110052700GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF LEVOSULPIRIDE - Gastric retentive oral dosage forms which provide both immediate and extended release of levosulpiride are described which may allow once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.03-03-2011
20110052699DRUG DELIVERY SYSTEM WITH STABILISING EFFECT - A drug delivery system also intended as unit dosage form comprising a thin water-soluble film matrix, wherein said film matrix comprises 03-03-2011
20110052698NOVEL MATERIAL WITH BACTERIOSTATIC PROPERTIES - The invention relates to a method for making a composite material including a porous polymer matrix containing HEMA monomers and in which silver nanoparticles are dispersed, and to the use thereof as an anti-microbial material.03-03-2011
20110052697Aptamer-Directed Drug Delivery - The present invention provides systems, methods, and compositions for targeted delivery of a therapeutic agent organs, tissues, cells, extracellular matrix components, and intracellular compartments. The present invention provides a complex comprising a therapeutic or diagnostic agent and a nucleic acid targeting moiety, wherein the agent non-covalently associates with base pairs of the nucleic acid targeting moiety. The invention provides targeted particles comprising a particle and an inventive complex. The present invention provides methods of designing, manufacturing, and using inventive complexes and targeted particles.03-03-2011
20110008441THERMORESPONSIVE ARGININE-BASED HYDROGELS AS BIOLOGIC CARRIERS - Cationic poly(ester amide) (PEA)-based hydrogels are provided. The hydrogels are fabricated from unsaturated L-arginine base poly(ester-amide) (UArg-PEA) precursors, pluronicDA precursors, or a combination of UArg-PEA and pluronicDA precursors at predetermined precursor composition ratios. PluronicDA/UArg-PEA hybrid hydrogels and pure pluronicDA based hydrogels are thermoresponsive and biodegradable, while pure UArg-PEA base hydrogels are biodegradable but not thermoresponsive. UArg-PEA based, pluronicDA based and hybrid hydrogels can be synthesized from unsaturated arginine-based PEA salts and/or unsaturated pluronic acid polymers. Unsaturated pluronic acid polymers can be synthesized by reacting pluronic acid with acryloylchloride to provided functional vinyl groups at the two chain ends of pluronic acid. The hydrogels can be used to carry and/or release molecules or compounds such as bioactive compounds, can function as biologic carriers for a variety of biomedical applications.01-13-2011
20110097406METHODS AND COMPOSITIONS FOR RETAINING ECM MATERIALS IN HYDROGELS - The present invention provides cell-laden and/or extracellular matrix material laden hydrogels for use in tissue engineering and methods for producing such hydrogels. In some particular embodiments, hydrogels comprise chondrocytes, which are typically encapsulated within the hydrogels. In many instances, such hydrogels are subjected to dynamic loading prior to being administered to a subject to treat a clinical condition that is helped by tissue engineering, including, but not limited to, cosmetic surgery such as craniofacial reconstruction surgery, and cartilage regeneration.04-28-2011
20100178344Extended-Release Composition Comprising a Somatostatin Derivative in Microparticles - The present invention relates to improved microparticles comprising a somatostatin analogue, a process of making said microparticles and to pharmaceutical compositions comprising the same.07-15-2010
20100166866MATRIX COMPOSITIONS FOR CONTROLLED DELIVERY OF DRUG SUBSTANCES - A novel matrix composition for pharmaceutical use. The matrix composition has been designed so that it is especially suitable in those situation where an improved bioavailability is desired and/or in those situation where a slightly or insoluble active substance is employed. Accordingly, a controlled release pharmaceutical composition for oral use is provided in the form of a coated matrix composition, the matrix composition comprising i) a mixture of a first and a second polymer that have plasticizing properties and which have melting points or melting intervals of a temperature of at the most 200° C., the first polymer being selected from the group consisting of polyethylene glycols and polyethylene oxides, and the second polymer being selected form block copolymer of ethylene oxide and propylene oxide including poly(ethylene-glycol-b-(DL-lactic acid-co-glycolic acid)-b-ethylene glycol (PEG-PLGA PEG), poly((DL-lactic acid-co-glycolic acid)-g-ethylene glycol) (PLGA-g-PEG), poloxamers and polyethylene oxide-polypropylene oxide (PEO-PPO), ii) a therapeutically, prophylactically and/or diagnostically active substance, the matrix composition being provided with a coating having at least one opening exposing at one surface of said matrix, wherein the active substance is released with a substantially zero order release.07-01-2010
20100068279BURN BANDAGE - The present invention provides a novel dressing for the treatment of skin injuries, particularly burns. The device comprises an gel-like interpenetrating network comprising polyvinyl alcohol and polyaspartate. Additional natural and synthetic components may be added to the network or to the surface of the device. The device provides cooling, protection from infection and delivery of therapeutic agents.03-18-2010
20110189291DENDRIMER HYDROGELS - Photoactivatable dendrimers and hydrogels formed therefrom include dendrimers to which polymer chains (e.g. polyethylene glycol, PEG) have been conjugated; and reactive photoactivatable groups attached to terminal functional groups of the polymer chains (e.g. hydroxyls of PEG). Exposure to a suitable wavelength of light activates the photoactivatable groups, which then crosslink with one another, thereby forming a hydrogel. The hydrogel may also include one or more agents of interest; or, in some embodiments, nanoparticles containing one or more agents of interest may be dispersed in the hydrogel. These formulations are well-suited for sustained or prolonged delivery of active agents, e.g. for the treatment of glaucoma by the sustained delivery of anti-glaucoma agents directly to the eye.08-04-2011
20100021544HYDROGEL AND BIOMEDICAL APPLICATIONS THEREOF - The invention relates to a method for preparing a cross-linked sterile and homogeneous hydrogel for injection, characterized in that it comprises the following steps: (a) preparing an aqueous solution containing a polymer derived from cellulose and at least one water-soluble polymer, the total polymer content ranging from 0.5 and 5 wt %, preferably from 1 to 4 wt % and more preferably from 1.5 to 3 wt %; (b) optionally adding sold particles; (c) pouring the resulting liquid mixture with the optional solid particles into a vessel and closing dais vessel using a water-tight and gas-tight system; and (d) exposing said vessel containing the liquid and the optional solid particles to a radiation dose of between 5 and 50 kGy, preferably between 20 and 30 kGy, and more preferably of about 25 kGy. The invention also relates to a hydrogel obtained according to the above method and to the use thereof in medical applications.01-28-2010
20120034305SOLID DISPERSING VACCINE COMPOSITION FOR ORAL DELIVERY - The invention disclosed herein relate to an oral vaccine in which the vaccine composition and adjuvant(s) are carried on a solid fast-dispersing dosage form. The vaccines are targeted toward mucosal tissue and the adjuvant serves to ensure sufficient residence time for the vaccine composition on the mucosal tissue to facilitate its absorption thereby. The fast-dispersing oral solid vaccine dosage form of the invention is particularly useful to administer the vaccine to patients that have difficulty swallowing medications. In one embodiment, the invention provides a fast disintegrating oral solid vaccine dosage form comprising: an immunogenic amount of an antigenic preparation, the antigenic preparation comprising a microsphere-antigen complex; an adjuvant, wherein the adjuvant enhances the absorption of the antigen or potentiates the immunogenic response; a mucoadhesive substance; and a low density dosage form matrix.02-09-2012
20110002998PROCESS FOR THE PRODUCTION OF INSECTICIDE-MODIFIED BEAD MATERIAL COMPOSED OF EXPANDABLE POLYSTYRENE AND INSECTICIDE-MODIFIED MOLDINGS OBTAINABLE THEREFROM - A process for the production of insecticide-modified bead material composed of expandable polystyrene (EPS) by extrusion, encompassing the steps of a) mixing, in a mixer, to incorporate a blowing agent and at least one insecticide from the group of the phenylpyrazoles, chlorfenapyr and hydramethylnon into a polymer melt which comprises at least one polystyrene, based on a vinylaromatic monomer, b) discharging the polymer melt comprising blowing agent, and c) pelletizing the polymer melt comprising blowing agent.01-06-2011
20090214652SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS - Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.08-27-2009
20110151004Injectable Microspheres - Injectable microspheres are obtained from double bond functionalized polyhydric alcohol ester by a method comprising dissolving the double bond functionalized esters in a hydrophobic organic solvent, forming an aqueous solution of stabilizer, forming an oil in water emulsion where the solution of stabilizer constitutes the continuous phase and the solution of ester constitutes the disperse phase and evaporating the organic solvent or from block copolymer of PGCLM and methoxy poly(ethylene glycol).06-23-2011
20090162439SILK FIBROIN COATING - The present invention is directed to compositions and methods for preventing or inhibiting biofilm formation on a solid substrate comprising an antimicrobial agent and a biofilm-degrading enzyme embedded in a matrix material.06-25-2009
20090317471CONTROLLED-RELEASE FORMULATIONS, METHOD OF MANUFACTURE, AND USE THEREOF - The present invention includes a controlled-release composition having a matrix. The matrix contains a pharmaceutically effective amount of an active agent or a pharmaceutically acceptable salt or solvate thereof, an ionic non-gelling matrix polymer, and a pH modifier. The ionic non-gelling matrix polymer is practically insoluble and unswellable at a first aqueous fluid pH and is soluble at a second aqueous fluid pH. The pH modifier is present in an amount to control the release of the active agent from the composition. The controlled-release composition is substantially free of a gelling or swellable excipient and does not contain a functional coating or a lipophilic component. The present invention also provides methods of making and using the controlled-release compositions.12-24-2009
20110045076LINEAR ORDER RELEASE POLYMER - Intravaginal drug delivery devices, including intravaginal rings, are provided herein. The devices comprise a polyether urethane composition and a pharmaceutically effective amount of at least one vaginally administrable drug homogeneously distributed throughout the polyether urethane. The devices are capable of exhibiting a substantially zero order release profile of drug over extended periods of time. Also disclosed are methods for making the devices and methods of using the devices to prevent or treat a biological condition.02-24-2011
20090252799MATERIALS AND METHODS FOR WOUND TREATMENT - The subject invention pertains to materials and methods for stopping or decreasing the blood flow from an open wound or medical or surgical procedure. Compositions of the invention comprise a salt form of a cross-linked polyacrylic acid. In one embodiment, the composition comprises a sodium salt of a polyacrylic acid. Compositions of the invention can also optionally comprise one or more different salt ferrates, and/or a cationic exchanger resins, and/or a silver compound. In an exemplified embodiment, a composition of the invention comprises sodium polyacrylate provided in a dry powdered form. Polyacrylate compositions of the invention can be applied directly to a wound or treatment site, or they can be incorporated into a wound dressing, such as a bandage. The clot or scab formed at a wound or treatment site treated with the present invention is extremely elastic and exhibits considerable tensile strength when stretched to the breaking point. The subject invention also concerns wound and surgical site dressings and coverings, and methods of using a composition of the invention to stop blood flow from an open wound or treatment site.10-08-2009
20100297238Multifunctional and Biologically Active Matrices from Multicomponent Polymeric Solutions - A functionalized electrospun matrix for the controlled-release of biologically active agents, such as growth factors, is presented. The functionalized matrix comprises a matrix polymer, a compatibilizing polymer and a biomolecule or other small functioning molecule. In certain aspects the electrospun polymer fibers comprise at least one biologically active molecule functionalized with low molecular weight heparin.11-25-2010
20090214651PRODUCTION OF POLYURETHANE FOAMS - The invention relates to a process for producing polyurethane foams, by frothing and drying specific polyurethane dispersions.08-27-2009
20090274762REHYDRATABLE PHARMACEUTICAL PRODUCT - A pharmaceutical product comprising lyophilised polymer matrix including a biologically active compound, of particular utility for embolisation, having improved rehydration properties is packaged in an airtight package under vacuum.11-05-2009
20100166865NANOPARTICLE COMPOSITIONS - A method of Nanoparticle-based therapy for a mammalian subject is disclosed. The method uses Nanoparticles and/or Nanoparticles with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating. The hydrophilic polymer coating is made up of polymer chains either covalently linked or surface adsorbed to the polymer components. After a desired Nanoparticle biodistribution is achieved, the affinity agent binds to the target surface and helps internalize the Nanoparticles07-01-2010
20080220066Anti-Viral Topical Gel Formulations Containing a Diuretic Such as Furosemide and/or a Cardiac Glycoside Such as Digoxin - An anti-viral topical gel formulation comprising at least one loop diuretic and/or cardiac glycoside in a gel carrier medium, said formulation capable of transdermal delivery of the said diuretic and/or glycoside.09-11-2008
20110318415Hollow Gold Nanospheres (HAuNSs) and HAuNSs-Loaded Microspheres Useful in Drug Delivery - A near-infrared mediated drug delivery system comprising a plurality of microspheres made of polymeric material, each sphere containing a plurality of hollow gold nanospheres together with drug product, wherein upon NIR irradiation, the drug product is released from the microsphere.12-29-2011
20120114756SUSTAINED-RELEASE DRUG CARRIER COMPOSITION - The present invention provides compositions for extended release of one or more active ingredients, comprising a lipid-saturated matrix formed from a non-biodegradable polymer or a block-co-polymers comprising a non-biodegradable polymer and a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.05-10-2012
20080279942Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker - A pharmaceutical preparation comprising an angiotensin II receptor antagonist, a calcium channel blocker and at least one substance selected from the group consisting of a hydrophilic polymer, an acidic substance and a fluidizing agent. The pharmaceutical preparation has improved dissolution properties.11-13-2008
20120207837BIOERODIBLE MATRIX FOR TISSUE INVOLVEMENT - Disclosed herein are polyurethane polymer matrices with a porosity of from about 20 microns to about 90 microns that are useful in promoting closure and protection of incision sites; supporting the lower pole position of breast implants; and providing a partial or complete covering of breast implants to provide a beneficial interface with host tissue and to reduce the potential for malpositioning or capsular contracture. The disclosed matrices can be seeded with mammalian cells.08-16-2012
20120009262MEDICAL APPARATUS AND METHOD FOR PRODUCING SAME - A medical device that includes at least one antibiotic in a macromolecular substance that swells upon contact with a solvent. Also, a method for preparing an antibiotic-containing medical device that involves contacting a medical device having at least a portion of the surface formed from a swellable macromolecular substance, with a solvent that swells the macromolecular substance, contacting the swollen macromolecular substance with at least one antibiotic, and removing the solvent from the swollen macromolecular substance.01-12-2012
20100303912Nanocell Drug Delivery System - Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.12-02-2010
20120064164EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS - The present invention provides extended release pharmaceutical compositions structured for once a day administration comprising skeletal muscle relaxant such as cyclobenzaprine or its pharmaceutically acceptable salt thereof that extends the release of the drug under in-vitro conditions for at least 8 to 12 hours. The invention also provides process for the preparation of such structured compositions.03-15-2012
20090028945Immunoisolative encapsulation system - A fundamental deficiency with current biological cell encapsulation technology is that passive material barriers cannot protect biological cells from exposure to cytokines and other small, diffusible cytotoxic molecules produced by activated immune cells, subsequently leading to biological cell destruction. The present invention provides an immunoisolative encapsulation system that actively and locally suppresses immune response using Fas receptor binding agents.01-29-2009
20100015230Bone Morphogenetic Protein Compositions - The present invention relates to compositions of bone morphogenetic proteins, particularly solid and liquid formulations of such proteins comprising one or more stabilizing excipients. The invention further provides methods of producing the compositions, kits comprising the compositions and methods of using the compositions in the treatment of diseases of skeletal and non-skeletal tissues.01-21-2010
20100098762Thermosensitive Pluronic Derivative Hydrogels With High Biodegradability And Biocompatibility For Tissue Regeneration And Preparation Method Thereof - The present invention relates to a thermosensitive pluronic derivative hydrogel for tissue regeneration in which a biodegradable polymer is introduced at one end or both ends of a pluronic polymer, a methacryloxyethyl trimellitic acid anhydride is conjugated to the biodegradable polymer, and a physiologically active substance is fixed to the methacryloxyethyl trimellitic acid anhydride, as well as a method for the preparation thereof. The pluronic derivative hydrogel according to the present invention exhibits high biodegradability due to the introduction of a biodegradable polymer while still maintaining the themosensitivity of the pluronic polymer itself and shows good biocompatibility owing to the coupling with a physiologically active substance capable of improving cell adhesion, proliferation and differentiation. Therefore, the pluronic derivative hydrogel according to the present invention can be effectively used in the regeneration of various kinds of tissues and organs.04-22-2010
20100291215DRUG DELIVERY MATRICES TO ENHANCE WOUND HEALING - Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGFβ superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.11-18-2010
20110104282New Therapy of Treatment of the Irritable Bowel Syndrome - The invention provides for new methods for treatment and diagnosis of irritable bowel syndrome (IBS). In particular, there is disclosed the use of a 05-05-2011
20100092561METHODS AND COMPOSITIONS USING SUBSTANCE P TO PROMOTE WOUND HEALING - Healing of wounds in mammalian tissue may be enhanced by the application of certain neuropeptides, optionally in combination with known growth promoting hormones. Exemplary neuropeptides include tachykinins, such as Substance P, Substance K, and the like, as well as calcitonin gene-related peptides. The compositions may further include a polymeric delivery carrier and are utilized by applying to the site of the wound. Wounds may be vascular or avascular wounds. The compositions promote elaboration of cellular matrices and development of cellular attachment mechanisms in addition to stimulating cellular proliferation.04-15-2010
20100028435INJECTABLE HYDROGEL WITH AN ENHANCED REMANENCE AND WITH AN ENHANCED ABILITY TO CREATE VOLUME - An injectable hydrogel includes a hydrogel matrix based on (a) single-phase-type cross-linked biopolymer(s), characterized in that previously cross-linked biopolymer hydrogel particles are co-cross-linked with the matrix. A method of and a process for production of the above-mentioned hydrogel are also disclosed.02-04-2010
20120219629COMPOSITIONS AND METHODS FOR CONTROLLED DELIVERY OF COMPOUNDS - Disclosed are methods, compositions and kits pertaining to controlled delivery of compounds. In certain aspects and embodiments the present technology relates to compositions and methods for controlled delivery of a compound such as a bioactive compound which involve exposing a matrix comprising the bioactive compound, a crosslinkable monomer and a polymerization initiator to an external stimulus; wherein the external stimulus causes crosslinking of the matrix. In some embodiments, the crosslinking causes a decrease in the release of the compound from the matrix.08-30-2012
20120171289DELIVERY SYSTEMS FOR BIOACTIVE AGENTS - The invention features a composition for the delivery of bioactive agents into cells that includes a delivery matrix, an anionic or zwitterionic compound, and a bioactive agent, e.g. a peptide, protein, or nucleic acid. The compositions of the invention can be used to deliver bioactive compounds, such as nucleic acids encoding immunostimulatory peptides and/or therapeutic proteins.07-05-2012
20120213853COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual.08-23-2012
20120213852COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual.08-23-2012
20120076858Orally Disintegrating Dosage Forms Containing Taste-Masked Active Ingredients - Orally disintegrating dosage forms, for the purpose of masking the taste, comprise active ingredients coated with a cationic polymer are described. The coating of polymers comprises N,N-diethylaminoethyl methacrylate (DEAEMA) polymerized therein. The taste-masked active ingredients are embedded into an orally disintegrating matrix.03-29-2012
20100166864MATRIX-BASED PULSE RELEASE PHARMACEUTICAL FORMULATION - The present invention relates to an oral pulse release pharmaceutical composition, which comprises a polymer matrix core, wherein at least one pharmaceutically active ingredient is distributed within the core and on the outer surface of the core. Amphetamine salts, among a number of other pharmaceutically active ingredients, can be formulated as a pharmaceutical composition described herein. The present invention also provides a method for preparing an immediate release component on a solid pharmaceutical formulation.07-01-2010
20080213370Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof - In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.09-04-2008
20100272809MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES - Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.10-28-2010
20100272808Shell-and-Core Dosage Form Approaching Zero-Order Drug Release - Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.10-28-2010
20100272807SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.10-28-2010
20090060999PROTEIN FORMULATION - The present invention relates to a new and improved low-concentration formulation of an active enamel substance, such as an enamel matrix, enamel matrix derivative and/or an enamel matrix protein, intended to be used as therapeutic, as prophylactic and/or as cosmetic agent. In the present invention, said active enamel substance is incorporated into a polymeric matrix, which is either suitable for cellular in-growth, or cell-occlusive. The active enamel substance can be incorporated into the polymeric matrix so that it is released by degradation of the polymeric matrix, by enzymatic action and/or by diffusion.03-05-2009
20090017121GASTRIC RETAINED GABAPENTIN DOSAGE FORM - A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.01-15-2009
20120231079METHODS AND COMPOSITIONS FOR CONTROLLED DELIVERY OF PHYTOCHEMICAL AGENTS - Compositions are provided that comprises a biocompatible polymeric matrix incorporating an effective amount of a phytochemical agent, a combination of phytochemical agents, or a phytochemical agent and one or more additional therapeutic agents. Methods of treating a cancer using the compositions are further provided.09-13-2012
20100323014NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER - A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, a poorly aqueous soluble non-ionizable cellulosic polymer, and a poorly aqueous soluble polymeric amphiphilic non-ionizable block copolymer.12-23-2010
20080299202Controlled-Delivery System of Pharmacologically Active Substances, Preparation Process and Medical Use Thereof - The invention concerns a system for biocompatible drug release comprising: (i) a polymer matrix; (ii) an inorganic component located inside said matrix and characterized by a lamellar structure with a net positive or negative charge able to intercalate (iii) a pharmacologically active principle into said lamellar structure, by establishing an ionic type of bond with it and thereby obtaining an intercalation compound. The preparation process for the release system comprises the stages of: treating the lamellar solid in such a way as to give it a net positive or negative charge, then combining it with the chosen active principle, also in an ionic form, to obtain an intercalation compound which is then mixed with the polymer matrix. The release system can be employed in making medical devices, like sutures, membranes, osteosynthesis plaques, multilayered devices, gels and drug delivery systems.12-04-2008
20080299203Solid Pharmaceutical Dosage Formulation - The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor.12-04-2008
20110002997PHOTOINITIATED TISSUE FILLER - Visible light-activated polymer cosmetic filler preparations useful in a variety of applications are provided. In some embodiments, the photo-activated polymer composition comprises a conventional polymeric material, such as HA, together with a modified, cross-linkable polymer, such as PEG or PEODA, to permit the formation of crosslinks within the polymer matrix in situ on exposure to a visible light source, such as an IPL device. The preparations provide for a more stabilized composition that is contourable during gelation.01-06-2011
20100233264TEMPERATURE AND pH-SENSITIVE BLOCK COPOLYMER HAVING EXCELLENT SAFTY IN VIVO AND HYDROGEL AND DRUG DELIVERY SYSTEM USING THEREOF - Disclosed herein are pH- and temperature-sensitive block copolymer with excellent safety and a method for preparing the same and a hydrogel and a drug carrier using the block copolymer. According to the present invention, the pH- and temperature-sensitive block copolymer comprises: obtained by copolymerization of: (a) polyethylene glycol-based compound (A); and (b) poly (β-amino ester)-based oligomer (B) or poly (amido amine)-based oligomer (C) or coupling of mixture (D) thereof. In order to control biodegradation rate, the block copolymer is mixed with poly (amido amine)-based oligomer instead of the poly (β-amino ester)-based oligomer and then coupling them.09-16-2010
20110038936SYSTEM AND METHOD FOR ELECTROSPUN DRUG LOADED BIODEGRADABLE CHEMOTHERAPY APPLICATIONS - Biodegradable resorbable drug delivery systems characterized by an electrospun biodegradable resorbable polymeric fiber matrix with at least one therapeutic agent incorporated into the fibers of the matrix, wherein the fiber matrix has an interfibrillar space of at least 65% by volume. Therapeutic methods for delivering a chemotherapeutic agent to body cavities from which a tumor has been excised and for strengthening weakened blood vessel walls are also disclosed.02-17-2011
20120269893Compositions Comprising Solid Particles Encapsulated In A Cross-Linked Silicone Matrix, And Methods Of Making The Same - The present invention relates to topical compositions containing solid particles that are stabilized via encapsulation into a cross-linked silicone matrix. The solid particles are preferably formed of a metal oxide, such as zinc oxide or titanium dioxide, and the cross-linked silicone matrix is preferably formed by cross-linking a silicone having branched reactive alkoxyl moieties in the presence of a stannous carboxylate cross-linking agent. The stabilized particles of the present invention can readily be used either alone or in combination with other skin care actives to form topical compositions with improved stability and performance.10-25-2012
20110223254FUNCTIONALIZED DIPHENOLICS AND ABSORBABLE POLYMERS THEREFROM - The present invention relates to dephenolic compounds, an example of which is shown below, which are functionalized, and polymers formed from the same.09-15-2011
20110236485SHELL AND CORE DOSAGE FORM APPROACHING ZERO-ORDER DRUG RELEASE - Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.09-29-2011
20080286360Chemically patterned hydrogels, manufacture and use thereof - A chemically patterned modified hydrogel formed from a modified hydrogel is provided. The hydrogel is conjugated with a multiphoton photocleavable molecule. The molecule has a multiphoton-labile protective group and a protected group. The protective group is cleavable upon multiphoton excitation to deprotect the protected group, without substantial polymerization of the hydrogel. The chemically patterned modified hydrogel is formed by exposing the modified hydrogel to multiphoton excitation to deprotect a portion of the protected groups.11-20-2008
20120321713GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF A NON-OPIOID ANALGESIC AND AN OPIOID ANALGESIC - Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.12-20-2012
20120087981Skin Engaging Member Comprising Encapsulated Actives - A skin engaging member suitable for use in a hair removal device, said skin engaging member comprising an encapsulated active contained in a matrix material, an encapsulated active comprising at least one nano-particle encapsulated in a micro-particle, wherein said nano-particle comprises a shell comprising a hydrophobic material, and wherein said micro-particle comprises a shell comprising a water sensitive material; and wherein at least one of said nano-particle and said micro-particle comprises a skin care active.04-12-2012
20100203141STIMULI-RESPONSIVE LOW SOLUBILITY HYDROGEL COPOLYMERS OF N-ISOPROPYL ACRYLAMIDE AND SYNTHESIS METHOD - Preferred embodiment stimuli-responsive low solubility copolymer hydrogel compositions of the invention include polymerized N-isopropylacrylamide and water insoluble monomer or oligomer repeating units. The repeating units are arranged within the polymer backbone of the copolymer hydrogel. In a preferred fabrication method, precursors of N-isopropylacrylamide and precursors of the water insoluble monomer of oligomer are solved in a liquid solvent to form a solution in a container. An initiator is added to the solution. Gas is bubbled through the solution, and the container is sealed. The solution is stirred while heating to a polymerization temperature and polymerization is permitted to complete to form the copolymer hydrogel composition.08-12-2010
20110159101SILYL ETHER-MODIFIED HYDROPHILIC POLYMERS AND USES FOR MEDICAL ARTICLES - Silane-functionalized hydrophilic polymers and polymeric matrices are described. Hydrophilic matrices can be formed from the polymers, and can be used in association with the preparation of implantable and injectable medical devices. Exemplary devices include those having a durable lubricious coating formed from the hydrophilic polymers.06-30-2011
20110159100FORMULATIONS AND METHODS FOR THE CONTROLLED RELEASE OF ACTIVE DRUG SUBSTANCES - Controlled release formulations and methods for preparing controlled release formulations for delivery of active drug substances are described herein. The formulations described herein may be employed to produce pharmaceutical compositions, such as controlled release dosage forms, adjusted to a specific administration scheme.06-30-2011
20080254124Controlled release composition - A composition for controlled delivery of at least one active substance into an aqueous medium by erosion at a preprogrammed rate of at least one surface of the composition, comprising a matrix comprising the active substance, the matrix being erodible in the aqueous medium in which the composition is to be used, and a coating having at least one opening exposing at least one surface of said matrix, the coating comprising a first cellulose derivative which has thermoplastic properties and which is substantially insoluble in the aqueous medium in which the composition is to be used, and at least one of a second cellulose derivative which is soluble or dispersible in water, a plasticizer, and a filler. The coating is a coating which crumbles and/or erodes upon exposure to the aqueous medium such as a body fluid. The first cellulose derivative may be, e.g., ethylcellulose, cellulose acetate, cellulose propionate or cellulose nitrate, and the second cellulose derivative may be, e.g. methylcellulose, carboxymethylcellulose or salts thereof, cellulose acetate phthalate, microcrystalline cellulose, ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose or hydroxymethylpropylcellulose.10-16-2008
20080254122Polymer release system - A pharmaceutical composition for controlled release of an active substance, the composition being a matrix composition of: (a) a substantially water soluble or crystalline polymer, (b) an active substance, and optionally, (c) one or more pharmaceutically acceptable excipients having a water solubility of at least 1 mg/ml at ambient temperature. The matrix composition does not contain a water dispersible or water soluble surface active agent that has at least one domain, which is compatible with the polymer in the matrix composition, and which substantially eliminates water diffusion between the interface between the polymer crystals.10-16-2008
20080248117Production of Solid Solutions Based on Poorly-Soluble Active Substances by a Short-Term Heating and Rapid Drying - A process for producing solid solutions in powder or granule form of slightly soluble substances in which the slightly soluble substance is in the form of a molecular dispersion in an excipient matrix, by atomizing a solution of the active ingredient and of the matrix excipients, which comprises heating an aqueous suspension of the slightly soluble substance in the presence of the matrix excipients to temperatures above the boiling point under atmospheric pressure, and dissolving the slightly soluble substance, and subsequently converting the solution of the slightly soluble substance and of the matrix excipients by atomizing and drying into a solid form, where the temperature of the spray solution before feeding into the atomizing apparatus is 90° C. to 350° C.10-09-2008
20080241246Cell-based therapies for treating liver disease - The invention provides, in part, methods for treating liver disease in a subject in need thereof. The invention further provides methods for improving liver function in a subject in need thereof, such as a subject with an ischemic liver or a cirrhotic liver. In some aspects, the methods of treatment comprise the administration of AC133+ alone or in combination with other cell populations.10-02-2008
20080233195SYNTHETIC TRITERPENOIDS AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH - The present invention concerns methods for stimulating the growth and repair of bone and cartilage using synthetic triterpenoids and tricyclic-bis-enones. Examples of suitable triterpenoids include CDDO, CDDO-Me, CDDO-Im, and CDDO-Ethylamide. Examples of tricyclic-bis-enones include TBE-31 and TBE-34.09-25-2008
20100074957INTRAOCULAR FORMULATION - Biodegradable therapeutic agent incorporating microspheres formulated in a high viscosity carrier suitable for intraocular administration to treat an ocular condition. The formulation can also be used to treat non-ocular conditions such as articular pathologies.03-25-2010
20080226725New and Advantageous Hydrogel Composition - New hydrogel, including a hydrogel containing cationic BSA is included in a vaccine to stimulate the immune system to increase the potency of the vaccine.09-18-2008
20080226724Prevention of hydrogel viscosity loss - The present invention comprises methods and compositions for decreasing or preventing viscosity loss in hydrogels.09-18-2008
20080226723Loadable Polymeric Particles for Therapeutic Use in Erectile Dysfunction and Methods of Preparing and Using the Same - Particles are provided for use in restorative procedures to treat erectile dysfunction. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be loaded to provide localized treatment with an active agent directed at restoration of normal penile erectile function and the treatment of erectile dysfunction. Moreover, such particles may be provided to a user with customized coloration or in various coded colors to indicate differing doses of active agent contained therein.09-18-2008
20080226722Gel Composition Comprising Charged Polymers - Aqueous gel compositions are disclosed which are useful as drug carriers for controlled delivery applications, such as for parenteral depot formulations. The gels comprise ionically charged microparticles, and preferably mixtures of oppositely charged microparticles. The microparticles can be loaded with active compounds, such as therapeutic peptides and proteins. The gels can be prepared by combining oppositely charged microparticles in the presence of water.09-18-2008
20080226721Porous Bodies and Method of Production Thereof - Porous bodies which are soluble or dispersible in non-aqueous media comprising a three dimensional open-cell lattice containing (a) 10 to 70% by weight of a polymeric material which is soluble in water immiscible non-aqueous media and (b) 30 to 90% by weight of a surfactant, said porous bodies having an intrusion volume as measured by mercury porosimetry of at least 09-18-2008
20090169628ARTICLE AND METHOD FOR FOCUSED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC MATERIALS - A microfiber extrudate and delivery process includes a bio-compatible polymer matrix forming a body of the microfiber extrudate, an exogenously excitable material arranged within the body, and an active load arranged within the body.07-02-2009
20080220065Compositions for treating foot odor and methods of use thereof - A composition and method of use thereof for treating foot odor caused by microbial organisms, wherein cupric polyatomic salt is utilized as the active ingredient, preferably in combination with a dispersal agent, and wherein healthy tissue is promoted and foot odor is eliminated.09-11-2008
20080213369SYNTHETIC PLATELETS - A synthetic platelet substitute that interacts with platelets and the (sub)endothelium, comprising: (a) a carrier molecule comprising lipidic particles with a cross-linked surface mesh, the lipidic particles comprising: an inner lipidic particle of pharmaceutically acceptable particle-forming lipids; hydrophilic polymer chains linked to the surface of the lipidic particle, the hydrophilic polymer chains comprising a crosslinkable end group at free ends thereof; and cross-linker groups linking the end groups of the hydrophilic polymer chains to form the cross-linked surface mesh; and (b) at least one receptor molecule attached to the surface of the carrier molecule. The receptor molecule can be a peptide moiety specific for ligands involved in platelet function.09-04-2008
20130171257EXTENDED RELEASE OPIOID ABUSE DETERRENT COMPOSITIONS AND METHODS OF MAKING SAME - This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.07-04-2013
20130115293Therapeutic Polymeric Nanoparticles Comprising Corticosteroids and Methods of Making and Using Same - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 50 weight percent of a corticosteroid; and about 50 to about 99 weight percent biocompatible polymer.05-09-2013
20100310659Compositions and Uses Thereof - Provided are solid dispersions, solid molecular complexes, salts and crystalline polymorphs involving propane-12-09-2010
20100316721Granular Sustained Release Preparation and Production Thereof - There is disclosed a novel sustained release granular resin-pharmaceutical composition comprising an ion exchange resin complexed with a pharmaceutical material wherein said complex is embedded into and on the surface of a diffusion barrier material. There is also disclosed a novel process for preparing the granulated complex wherein an aqueous granulating vehicle is employed to form the complex and the granulated product, thereby avoiding the use of coatings and large amounts of organic solvents in the process.12-16-2010
20100316720Use of an extract from snow algae in cosmetic or dermatological formulations - The present invention relates to the use of an extract from snow algae, especially an extract from 12-16-2010
20100316719B-1,3-GLUCAN-DERIVED POLYALDEHYDE/POLYAMINE HYDROGEL - The present invention provides a combination product which comprises: 12-16-2010
20130095183BONE GRAFT SYSTEM - The bone graft system comprises a solid inorganic component, which is bone graft material, and a hydrogel. The hydrogel contains >2 ppm of silicon ions, calculated as parts by weight of Si per million of the aqueous component of the hydrogel. Preferably, the solid inorganic component comprises hydroxyapatite or a silicon-containing hydroxyapatite, and may be a silicon-containing hydroxyapatite having a Ca/P ratio in the range 2.05 to 2.55 and a Ca/(P+Si) molar ratio less than 1.66. Bone healing is promoted by delivery of silicon ion release from the hydrogel and by the solid inorganic component stimulating cell behavior.04-18-2013
20110311631CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL EMPLOYING A COATING COMPRISING A POLYMER MIXTURE AND EXCIPIENTS - The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol. The coating layer comprises a polymeric portion consisting of a water-insoluble neutral vinyl polymer or vinyl copolymer and an amino methacrylate copolymer and an excipients portion consisting of a lubricant, an emulsifier, a plasticizer and optionally a cellulosic compound.12-22-2011
20110311630Novel embedment particles for inhalation - The invention relates to the preparation of inhalable powders which exhibit a delayed release of active substance and processes for preparing them as well as medicaments that can be produced using these inhalable powders.12-22-2011
20120034306POLYMERIC DRUG DELIVERY SYSTEMS AND PROCESSES FOR PRODUCING SUCH SYSTEMS - The subject invention relates to implants for delivery of therapeutic agents such as opioids, and the manufacture and uses of such implants.02-09-2012
20120045513POLYMER-BASED, SUSTAINED RELEASE DRUG DELIVERY SYSTEM - Disclosed is a sustained release system that includes a polymer and a pharmaceutically active agent dispersed in the polymer. The agent is in granular or particulate form, and has a rate of release from the system that is limited primarily by the rate at which the agent dissolves from the granules into the polymer matrix. Advantageously, the polymer is permeable to the agent and is non-release-rate-limiting with respect to the rate of release of the agent from the polymer.02-23-2012
20090252798MATRIX-GEL GRAFT WITHOUT CELLS - A cell-free graft contains (i) a cohesive, scaffold-forming matrix with open porosity containing a biologically and pharmaceutically acceptable material, and (ii) a gel of a biologically and pharmaceutically acceptable material. The cell-free graft is produced by (v) contacting the matrix with the gel, and (vi) drying the matrix-gel complex formed in (v). The cell-free graft can be used for covering and increasing the viscoelasticity of defects, for tissue regeneration and in particular for regenerating mesenchymal tissue, especially cartilage and/or bone.10-08-2009
20100015229Pharmaceutical compositions - A process for the production of a composition comprising a water-insoluble statin which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble statin ii) a water soluble carrier, iii) a solvent for each of the statin and the carrier, and b) spray-drying the mixture to remove the or each solvent and obtain a substantially solvent-free nano-dispersion of the statin in the carrier.01-21-2010
20090053313Process for the preparation of a polymeric hydrogel based on a highly purified polyvinylalcohol and uses thereof - The present invention relates to the preparation of a completely biocompatible and injectable, crosslinked polymeric hydrogel based on a polyvinyl alcohol. Said polymer, which is produced in a highly purified form, proved particularly suitable for the preparation of a filler to be employed in medicine and cosmetics, for the purpose of filling, correcting or treating deficits of different kind, origin and size of the soft tissues.02-26-2009
20120087982EXTENDED RELEASE OPIOID ABUSE DETERRENT COMPOSITIONS AND METHODS OF MAKING SAME - This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.04-12-2012
20120093930ARTICLE AND METHOD FOR FOCUSED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC MATERIALS - A microfiber extrudate and delivery process includes a bio-compatible polymer matrix forming a body of the microfiber extrudate, an exogenously excitable material arranged within the body, and an active load arranged within the body.04-19-2012
20120093929Opioid Composition for Treating Skin Lesions - The present invention relates to a composition, comprising (i) a matrix made of polymeric nanofibers, and (ii) an opioid agonist within the matrix.04-19-2012

Patent applications in class Synthetic polymer

Patent applications in all subclasses Synthetic polymer